Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Dividend, Quarterly Report, Recognition, Study Results, and New Drug Application - Research Report on Pfizer, Lilly, Regeneron,



     Dividend, Quarterly Report, Recognition, Study Results, and New Drug
  Application - Research Report on Pfizer, Lilly, Regeneron, Vertex, and GSK

PR Newswire

NEW YORK, Nov. 1, 2013

NEW YORK, Nov. 1, 2013 /PRNewswire/ -- Editor Note: For more information about
this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Incorporated
(NASDAQ: VRTX), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may
access these reports free of charge – including full price targets, industry
analysis and analyst ratings – via the links below.

Pfizer Inc. Research Report

On October 24, 2013, Pfizer Inc. (Pfizer) announced that its Board of
Directors has declared a Q4 2013 dividend of $0.24 per common share. Pfizer
reported that the dividend is payable on December 3, 2013, to shareholders of
record at the close of business on November 8, 2013. The Full Research Report
on Pfizer Inc. – including full detailed breakdown, analyst ratings and price
targets – is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/d702_PFE]

--

Eli Lilly and Company Research Report

On October 23, 2013, Eli Lilly and Company (Lilly) released its Q3 2013
results. Lilly registered total revenue of $5.8 billion, 6.0% YoY in Q3 2013.
The Company posted net income of $1.2 billion in Q3 2013, down compared to net
income of $1.3 billion in Q3 2012. Lilly reported diluted EPS of $1.11 in Q3
2013, compared to diluted EPS of $1.18 in Q3 2012. Commenting on the results,
John C. Lechleiter, Ph.D., Chairman, President, and CEO of Lilly, said, "As we
navigate through a period of expiring patents for some of our largest
products, Lilly continues to deliver solid financial results and to advance
our late-stage pipeline, with four regulatory filings completed this year
alone." Lechleiter continued, "We are successfully executing our strategy
which will enable us to return to growth after 2014 by bringing to the market
new medicines that make a real difference for patients." The Full Research
Report on Eli Lilly and Company – including full detailed breakdown, analyst
ratings and price targets – is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/977d_LLY]

--

Regeneron Pharmaceuticals, Inc. Research Report

On October 24, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) announced
that it has been ranked by Science magazine as the #1 employer in the global
biopharmaceutical industry for the second consecutive year in the journal's
annual Top Employers Survey. Leonard S. Schleifer, M.D., Ph.D., President and
CEO of Regeneron, commented, "Regeneron's tremendous growth and our current
expansion plans are undoubtedly thanks to our employees. If we are the best
place to work, it is because we have the best employees and a culture where
they feel empowered and challenged." The Full Research Report on Regeneron
Pharmaceuticals, Inc. – including full detailed breakdown, analyst ratings and
price targets – is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/8ea7_REGN]

--

Vertex Pharmaceuticals Incorporated Research Report

On October 18, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced
12-week results from an ongoing Phase 2b study of VX-509, an investigational
oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in
people with active rheumatoid arthritis (RA) taking methotrexate. According to
Vertex, the study met its primary endpoints of both the proportion of people
who achieved at least a 20% improvement in signs and symptoms of RA, as
measured by the ACR improvement criteria (ACR20), and the change from baseline
in Disease Activity Score for 28 joints (DAS28). Robert Kauffman, M.D., Ph.D.,
Senior Vice President and Chief Medical Officer at Vertex, said, "These
results are encouraging and provide further support for the development of
VX-509 as a new approach to treating RA and potentially other immune-mediated
and inflammatory diseases by selectively targeting JAK3." Kauffman continued,
"In this study, treatment with VX-509 showed good tolerability and resulted in
significant improvements in the signs and symptoms of RA across all doses
tested. We look forward to the presentation of these data at the ACR annual
meeting later this month." The Full Research Report on Vertex Pharmaceuticals
Incorporated – including full detailed breakdown, analyst ratings and price
targets – is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/e696_VRTX]

--

GlaxoSmithKline plc Research Report

On October 23, 2013, GlaxoSmithKline plc (GSK) announced that it has submitted
a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for
the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate
(FF), administered using the ELLIPTA dry powder inhaler. GSK reported that the
NDA has been submitted for FF monotherapy (100mcg and 200mcg doses) as a
once-daily inhaled dry powder maintenance treatment of asthma as prophylactic
therapy in patients aged 12 years and older. The Company reported that
regulatory filings for FF monotherapy are planned in other countries from 2014
onwards. The Full Research Report on GlaxoSmithKline plc – including full
detailed breakdown, analyst ratings and price targets – is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Website: http://www.AnalystsCorner.com
Contact: Joe Thomas, +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement